Dermatitis

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.

Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.

Fish oil supplementation during pregnancy was associated with children having a lower or higher risk for developing atopic dermatitis depending on the mother’s genotype, according to a study.

Nemolizumab doses of 30 mg and 60 mg with topical corticosteroid treatment yielded positive results in adolescent patients with prurigo nodularis, according to a study.

Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.

Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.

New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.

The National Institute for Health and Care Excellence has recommended Ebglyss for the treatment of moderate to severe atopic dermatitis in the National Health Service England, according to an Almirall press release.

Instead of patch testing with all allergens in any given group, using an optimized subset of allergens to test for allergic contact dermatitis can provide a similar level of care at a reduced cost, according to a study.

Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.